Last reviewed · How we verify

NCT06761261: LIVERPED

Acute Hepatitis in Pediatrics

Recruiting now Last updated 7 January 2025
What this trial tests

trial in Hepatitis in 437 participants. Currently enrolling.

Timeline
16 October 2023
Primary endpoint
31 December 2028
31 December 2028

Quick facts

Lead sponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment437
Start date16 October 2023
Primary completion31 December 2028
Estimated completion31 December 2028
Sites2 locations across Italy

Conditions studied

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna — full company profile →

Who can join

Under 17, any sex, with Hepatitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to investigate wich symptoms and blood test characteristics acute hepatitis manifests in pediatric age. The study will be conducted because acute hepatitis is not an easily and clearly recognized disease in children. This study aims to better characterize this disease by describing the frequency of the different symptoms with which it can manifest and the changes it causes in blood tests. It also aims to assess the occurrence of any complications of pediatric acute hepatitis. The study is observational, so it is limited to collecting data and analyzing the patient's clinical course without interfering with normal clinical practice.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Hepatitis

Currently open trials in the same condition.

Other IRCCS Azienda Ospedaliero-Universitaria di Bologna trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06761261.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing